| Title |
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialMacrophage-Targeted Immunotherapy
|
|---|---|
| Published in |
Clinical Cancer Research, June 2021
|
| DOI | 10.1158/1078-0432.ccr-20-4862 |
| Pubmed ID | |
| Authors |
Reetta Virtakoivu, Jenna H. Rannikko, Miro Viitala, Felix Vaura, Akira Takeda, Tapio Lönnberg, Jussi Koivunen, Panu Jaakkola, Annika Pasanen, Shishir Shetty, Maja J.A. de Jonge, Debbie Robbrecht, Yuk Ting, Tanja Skyttä, Anna Minchom, Sirpa Jalkanen, Matti K. Karvonen, Jami Mandelin, Petri Bono, Maija Hollmén |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 6 | 35% |
| United States | 3 | 18% |
| Denmark | 1 | 6% |
| Unknown | 7 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 71% |
| Scientists | 4 | 24% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 52 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 23% |
| Researcher | 9 | 17% |
| Student > Postgraduate | 3 | 6% |
| Student > Bachelor | 3 | 6% |
| Student > Ph. D. Student | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 20 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 10 | 19% |
| Medicine and Dentistry | 7 | 13% |
| Agricultural and Biological Sciences | 5 | 10% |
| Immunology and Microbiology | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Other | 3 | 6% |
| Unknown | 20 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 95. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 November 2023.
All research outputs
#453,341
of 26,017,215 outputs
Outputs from Clinical Cancer Research
#237
of 13,372 outputs
Outputs of similar age
#12,643
of 463,336 outputs
Outputs of similar age from Clinical Cancer Research
#8
of 168 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,372 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 463,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 168 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.